Enlivex Announces 1-for-16 Reverse Share Split Effective October 27, 2026

Nes-Ziona, Israel, Oct. 22, 2026 /CourierPR/ -- Enlivex Ltd., a quality longevity company powered by a prediction markets treasury, announced on October 27, 2026, a 1-for-16 reverse share split. This move will affect the company's ordinary shares, reducing the number of authorized shares from 158,333,333 to 9,895,833. The par value of each share will increase from NIS 6.00 to NIS 96.00.

As a result of the reverse split, the number of Enlivex’s issued and outstanding ordinary shares will decrease from 24,511,905 to approximately 1,531,995, subject to adjustment based on the rounding of fractional shares. No fractional ordinary shares will be issued; instead, all fractional shares will be rounded up to the nearest whole ordinary share. The new CUSIP number for the ordinary shares following the reverse split will be M4130Y205.

The reverse split will not affect any shareholder’s ownership percentage of the ordinary shares, except for adjustments that may result from the rounding of fractional shares. The per share exercise price and the number of shares issuable upon the exercise of all of Enlivex’s outstanding warrants and options will also be proportionately adjusted.

The company's ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol “ENLV.” Enlivex is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The company operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum.

Forward-looking statements within the release include the company's plans for cost reduction, the expected timing and amount of related restructuring charges, the need for and ability to obtain additional financing, the progress, enrollment, design, and expected timing of completion of the company's Phase 2b clinical trial of ALLOCETRA™, the anticipated timing of topline six-month data from the Phase 2b trial, and the potential benefits of RMAT designation. The company also discusses its digital asset treasury strategy and the assets to be held by the company, as well as the expected future market, price, trading activity, and liquidity of the RAIN token.

The release is in accordance with the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The company undertakes no obligation to update or revise any of these statements, except as required by applicable law.